Application of Network Pharmacology in the Treatment of Neurodegenerative Diseases with Traditional Chinese Medicine

Qiang Chen; Guanghui Chen; Qianyan Wang

doi:10.1055/a-2512-8928

Planta Medica, Inhaltsverzeichnis

CC BY 4.0 · Planta Med 2025; 91(05): 226-237
DOI: 10.1055/a-2512-8928

Reviews

Application of Network Pharmacology in the Treatment of Neurodegenerative Diseases with Traditional Chinese Medicine

Autoren

Qiang Chen

¹Department of Pharmacy, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Guanghui Chen

²Department of Pharmacy, Renmin Hospital, Wuhan University, Wuhan, Hubei, China
Qianyan Wang

³Liyuan Cardiovascular Center, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Abstract

In recent years, the incidence of neurodegenerative diseases, including Alzheimerʼs disease, Parkinsonʼs disease, Huntingtonʼs disease, and amyotrophic lateral sclerosis, has exhibited a steadily rising trend, which has posed a major challenge to the global public health. Traditional Chinese medicine, with its multicomponent and multitarget characteristics, offers a promising approach to treating neurodegenerative diseases. However, comprehensively elucidating the complex mechanisms underlying traditional Chinese medicine formulations remains challenging. As an emerging systems biology method, network pharmacology has provided a vital tool for revealing the multitarget mechanisms of traditional Chinese medicine through high-throughput technologies, molecular docking, and network analysis. This paper reviews the advancements in the application of network pharmacology in treating neurodegenerative diseases using traditional Chinese medicine, analyzes the current status of relevant databases and technological methods, discusses the limitations, and proposes future directions to promote the modernization of traditional Chinese medicine and the development of precision medicine.

Keywords

neurodegenerative diseases - traditional Chinese medicine - network pharmacology - therapeutic targets

Volltext

Referenzen

References
1 Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008; 4: 682-690
2 Liu F, Bai Y, Wu X, Wan Y, Luo S, Zhang L, Li T, Tang H, Tang X, Chen R, Chen Q, Xie Y, Guo P. Network pharmacology combined with experimental validation reveals the mechanism of action of cangerzisan on allergic rhinitis. J Ethnopharmacol 2024; 335: 118611
3 Zhong Y, Wen W, Luo Z, Cheng N. A multi-component, multi-target, and multi-pathway prediction method for Chinese medicine based on the combination of mass spectrometry analysis and network analysis: An example using Weifuchun. J Chromatogr A 2024; 1731: 465164
4 Zhou ZD, Kihara AH. Neurodegenerative diseases: Molecular mechanisms and therapies. Int J Mol Sci 2023; 24: 13721
5 Ricci C. Neurodegenerative disease: From molecular basis to therapy. Int J Mol Sci 2024; 25: 967
6 Wareham LK, Liddelow SA, Temple S, Benowitz LI, Di Polo A, Wellington C, Goldberg JL, He Z, Duan X, Bu G, Davis AA, Shekhar K, Torre A, Chan DC, Canto-Soler MV, Flanagan JG, Subramanian P, Rossi S, Brunner T, Bovenkamp DE, Calkins DJ. Solving neurodegeneration: Common mechanisms and strategies for new treatments. Mol Neurodegener 2022; 17: 23
7 Buccellato FR, DʼAnca M, Serpente M, Arighi A, Galimberti D. The role of glymphatic system in Alzheimerʼs and Parkinsonʼs disease pathogenesis. Biomedicines 2022; 10: 2261
8 Singh K, Gupta JK, Kumar S, Soni U. A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Bioactive Peptides. Curr Protein Pept Sci 2024; 25: 507-526
9 Iacobucci G. Donanemab leads to modest slowing of Alzheimerʼs progression, study finds. BMJ 2023; 382: 1659
10 Mahboob A, Ali H, Alnaimi A, Yousef M, Rob M, Al-Muhannadi NA, Senevirathne DKL, Chaari A. Immunotherapy for Parkinsonʼs disease and Alzheimerʼs disease: A promising disease-modifying therapy. Cells 2024; 13: 1527
11 Mitchell CL, Kurouski D. Novel strategies in Parkinsonʼs disease treatment: A review. Front Mol Neurosci 2024; 17: 1431079
12 Shi F, He Y, Chen Y, Yin X, Sha X, Wang Y. Comparative analysis of multiple neurodegenerative diseases based on advanced epigenetic aging brain. Front Genet 2021; 12: 657636
13 GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: An analysis for the Global Burden of Disease Study 2019. Lancet Public Health 2022; 7: e105-e125
14 Ren B, Cheng F, Wang X, Wan Y, Ji W, Du X, Zhang S, Liu S, Ma C, Xiong Y, Hao G, Wang Q. Possible mechanisms underlying treatment of Alzheimerʼs disease with Traditional Chinese Medicine: Active components, potential targets and synthetic pathways of Bulao Elixir. J Tradit Chin Med 2020; 40: 484-496
15 Krawczuk D, Kulczynska-Przybik A, Mroczko B. Clinical application of blood biomarkers in neurodegenerative diseases-present and future perspectives. Int J Mol Sci 2024; 25: 8132
16 Wang Y, Zheng L. Protocatechuic acid, the main effective monomer in Wuqi Powder, can inhibit gastric ulcers induced by acetic acid and Helicobacter pylori . Am J Transl Res 2023; 15: 151-164
17 Huang L, Wang Q, Duan Q, Shi W, Li D, Chen W, Wang X, Wang H, Chen M, Kuang H, Zhang Y, Zheng M, Li X, He Z, Wen C. TCMSSD: A comprehensive database focused on syndrome standardization. Phytomedicine 2024; 128: 155486
18 Ru J, Li P, Wang J, Zhou W, Li B, Huang C, Li P, Guo Z, Tao W, Yang Y, Xu X, Li Y, Wang Y, Yang L. TCMSP: A database of systems pharmacology for drug discovery from herbal medicines. J Cheminform 2014; 6: 13
19 Fan M, Jin C, Li D, Deng Y, Yao L, Chen Y, Ma YL, Wang T. Multi-level advances in databases related to systems pharmacology in traditional Chinese medicine: A 60-year review. Front Pharmacol 2023; 14: 1289901
20 Xu HY, Zhang YQ, Liu ZM, Chen T, Lv CY, Tang SH, Zhang XB, Zhang W, Li ZY, Zhou RR, Yang HJ, Wang XJ, Huang LQ. ETCM: An encyclopaedia of traditional Chinese medicine. Nucleic Acids Res 2019; 47: D976-D982
21 Zhang S, Zhang J, Wei D, An H, Liu W, Lai Y, Yang T, Shao W, Huang Y, Wang L, Dou F, Peng D, Zhang Z. Dengzhan Shengmai capsules and their active component scutellarin prevent cognitive decline in APP/PS1 mice by accelerating Abeta aggregation and reducing oligomers formation. Biomed Pharmacother 2020; 121: 109682
22 Chen T, Lei Y, Li M, Liu X, Zhang L, Cai F, Gong X, Zhang R. Network pharmacology to unveil the mechanism of suanzaoren decoction in the treatment of Alzheimerʼs with diabetes. Hereditas 2024; 161: 2
23 Du Y, Guo J, Zhou Y, Yan S, Xu B, Wang Y, Lu D, Ma Z, Chen Q, Tang Q, Zhang W, Zhu J, Huang Y, Yang C. Revealing the mechanisms of Byu dMar 25 in the treatment of Alzheimerʼs disease through network pharmacology, molecular docking, and in vivo experiment. ACS Omega 2023; 8: 25066-25080
24 Li SQ, Min DY, Jiang JW, Li XY, Yang XN, Gu WB, Jiang JH, Chen LH, Nan H, Chen ZY. Network pharmacology-based exploration of molecular mechanisms underlying therapeutic effects of Jianpi Huatan Quyu recipe on chronic heart failure with spleen Qi deficiency syndrome. World J Cardiol 2024; 16: 422-435
25 Wang F, Liu Y, Li Y, Yang X, Zhao J, Yang B, Tang D, Zhang C, He Z, Ming D, Zhu X. Combining network pharmacology and experimental verification to ascertain the mechanism of action of Asparagus officinalis against the brain damage caused by fluorosis. Environ Toxicol 2024; 1: 1-15
26 Kuhn M, Szklarczyk D, Franceschini A, Campillos M, von Mering C, Jensen LJ, Beyer A, Bork P. STITCH 2: an interaction network database for small molecules and proteins. Nucleic Acids Res 2010; 38: D552-556
27 Szklarczyk D, Santos A, von Mering C, Jensen LJ, Bork P, Kuhn M. STITCH 5: Augmenting protein-chemical interaction networks with tissue and affinity data. Nucleic Acids Res 2016; 44: D380-D384
28 Shi YY, Chen ZQ, Huang LX, Gong YL, Shi L. A network pharmacology approach to reveal the key ingredients in Scrophulariae Radix (SR) and their effects against Alzheimerʼs disease. Heliyon 2024; 10: e24785
29 Olatunde A, Nigam M, Singh RK, Panwar AS, Lasisi A, Alhumaydhi FA, Jyoti Kumar V, Mishra AP, Sharifi-Rad J. Cancer and diabetes: The interlinking metabolic pathways and repurposing actions of antidiabetic drugs. Cancer Cell Int 2021; 21: 499
30 Wu C, Huang ZH, Meng ZQ, Fan XT, Lu S, Tan YY, You LM, Huang JQ, Stalin A, Ye PZ, Wu ZS, Zhang JY, Liu XK, Zhou W, Zhang XM, Wu JR. A network pharmacology approach to reveal the pharmacological targets and biological mechanism of compound kushen injection for treating pancreatic cancer based on WGCNA and in vitro experiment validation. Chin Med 2021; 16: 121
31 Gu LL, Lu JQ, Li Q, Wu NZ, Zhang LX, Li HX, Xing WM, Zhang XY. A network-based analysis of key pharmacological pathways of Andrographis paniculata acting on Alzheimerʼs disease and experimental validation. J Ethnopharmacol 2020; 251: 112488
32 Hampel H, Vergallo A, Caraci F, Cuello AC, Lemercier P, Vellas B, Giudici KV, Baldacci F, Hänisch B, Haberkamp M, Broich K, Nisticò R, Emanuele E, Llavero F, Zugaza JL, Lucía A, Giacobini E, Lista S. Alzheimer Precision Medicine Initiative. Future avenues for Alzheimerʼs disease detection and therapy: Liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. Neuropharmacology 2021; 185: 108081
33 Recabarren D, Alarcón M. Gene networks in neurodegenerative disorders. Life Sci 2017; 183: 83-97
34 Mendez D, Gaulton A, Bento AP, Chambers J, De Veij M, Félix E, Magariños MP, Mosquera JF, Mutowo P, Nowotka M, Gordillo-Marañón M, Hunter F, Junco L, Mugumbate G, Rodriguez-Lopez M, Atkinson F, Bosc N, Radoux C, Segura-Cabrera A, Hersey A, Leach AR. ChEMBL: Towards direct deposition of bioassay data. Nucleic Acids Res 2019; 47: D930-D940
35 Bento AP, Gaulton A, Hersey A, Bellis LJ, Chambers J, Davies M, Krüger FA, Light Y, Mak L, McGlinchey S, Nowotka M, Papadatos G, Santos R, Overington JP. The ChEMBL bioactivity database: An update. Nucleic Acids Res 2014; 42: D1083-D1090
36 Iqbal D, Rehman MT, Bin Dukhyil A, Rizvi S, Al Ajmi MF, Alshehri BM, Banawas S, Khan MS, Alturaiki W, Alsaweed M. High-throughput screening and molecular dynamics simulation of natural product-like compounds against Alzheimerʼs disease through multitarget approach. Pharmaceuticals (Basel) 2021; 14: 937
37 Wang Q, Pang Y, Yang H, Zhang X, Nie W, Zhou J, Chen R. Investigating the mechanism of Fuling-Banxia-Dafupi in the treatment of diabetic kidney disease using network pharmacology and molecular docking. Nat Prod Res 2024; 1-6
38 Zhang Z, Gao J, Wang J, Mi Z, Li H, Dai Z, Pan Y, Dong J, Chen S, Lu S, Tan X, Chen H. Mechanism of Zhishi Xiebai Guizhi decoction to treat atherosclerosis: Insights into experiments, network pharmacology and molecular docking. J Ethnopharmacol 2024; 333: 118466
39 Xiao G, Yang M, Zeng Z, Tang R, Jiang J, Wu G, Xie C, Jia D, Bi X. Investigation into the anti-inflammatory mechanism of Pothos chinensis (Raf.) Merr. By regulating TLR4/MyD88/NF-kappaB pathway: Integrated network pharmacology, serum pharmacochemistry, and metabolomics. J Ethnopharmacol 2024; 334: 118520
40 Pariary R, Shome G, Dutta T, Roy A, Misra AK, Jana K, Rastogi S, Senapati D, Mandal AK, Bhunia A. Enhancing amyloid beta inhibition and disintegration by natural compounds: A study utilizing spectroscopy, microscopy and cell biology. Biophys Chem 2024; 313: 107291
41 Brookmeyer R, Abdalla N, Kawas CH, Corrada MM. Forecasting the prevalence of preclinical and clinical Alzheimerʼs disease in the United States. Alzheimers Dement 2018; 14: 121-129
42 Guo Y, Fan Z, Zhao S, Yu W, Hou X, Nie S, Xu S, Zhao C, Han J, Liu X. Brain-targeted lycopene-loaded microemulsion modulates neuroinflammation, oxidative stress, apoptosis and synaptic plasticity in beta-amyloid-induced Alzheimerʼs disease mice. Neurol Res 2023; 45: 753-764
43 De Strooper B, Karran E. The cellular phase of Alzheimerʼs disease. Cell 2016; 164: 603-615
44 Cummings J, Lee G, Zhong K, Fonseca J, Taghva K. Alzheimerʼs disease drug development pipeline: 2021. Alzheimers Dement (N Y) 2021; 7: e12179
45 Wang Y, Jiang J, Chen S, Chen Q, Yan X, Shen X. Elucidating the therapeutic mechanism of Hengqing II decoction in Alzheimerʼs disease using network pharmacology and molecular docking techniques. Fitoterapia 2024; 174: 105860
46 Zhang M, Zheng H, He J, Zhang M. Network pharmacology and in vivo studies reveal the neuroprotective effects of paeoniflorin on Alzheimerʼs disease. Heliyon 2023; 9: e21800
47 Xu W, Ren B, Zhang Z, Chen C, Xu T, Liu S, Ma C, Wang X, Wang Q, Cheng F. Network pharmacology analysis reveals neuroprotective effects of the Qin-Zhi-Zhu-Dan formula in Alzheimerʼs disease. Front Neurosci 2022; 16: 943400
48 Qiu ZK, Zhou BX, Pang J, Zeng WQ, Wu HB, Yang F. The network pharmacology study and molecular docking to investigate the potential mechanism of Acoritataninowii Rhizoma against Alzheimerʼs disease. Metab Brain Dis 2023; 38: 1937-1962
49 Soleimani Zakeri NS, Pashazadeh S, MotieGhader H. Drug repurposing for Alzheimerʼs disease based on protein-protein interaction network. Biomed Res Int 2021; 2021: 1280237
50 Siderowf A. Parkinsonʼs disease: Clinical features, epidemiology and genetics. Neurol Clin 2001; 19: 565-578 vi
51 Tapias V, Hu X, Luk KC, Sanders LH, Lee VM, Greenamyre JT. Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective dopamine neurodegeneration in part via iNOS-mediated nitric oxide production. Cell Mol Life Sci 2017; 74: 2851-2874
52 Becerra-Calixto A, Mukherjee A, Ramirez S, Sepulveda S, Sinha T, Al-Lahham R, De Gregorio N, Gherardelli C, Soto C. Lewy body-like pathology and loss of dopaminergic neurons in midbrain organoids derived from familial Parkinsonʼs disease patient. Cells 2023; 12: 625
53 Henriques A, Rouviere L, Giorla E, Farrugia C, El Waly B, Poindron P, Callizot N. Alpha-synuclein: The spark that flames dopaminergic neurons, in vitro and in vivo evidence. Int J Mol Sci 2022; 23: 9864
54 Kwon DK, Kwatra M, Wang J, Ko HS. Levodopa-induced dyskinesia in Parkinsonʼs disease: Pathogenesis and emerging treatment strategies. Cells 2022; 11: 3736
55 Liu Z, Zhao J, Yang S, Zhang Y, Song L, Wu N, Liu Z. Network pharmacology and absolute bacterial quantification-combined approach to explore the mechanism of Tianqi Pingchan granule against 6-OHDA-induced Parkinsonʼs disease in rats. Front Nutr 2022; 9: 836500
56 Wu Y, Bai Y, Lu Y, Zhang ZN, Zhao Y, Huang SR, Tang LL, Liang Y, Hu Y, Xu CC. Transcriptome sequencing and network pharmacology-based approach to reveal the effect and mechanism of Ji Chuan Jian against Parkinsonʼs disease. BMC Complement Med Ther 2023; 23: 182
57 Zhang W, Chen JY, Liu HQ. Network pharmacology and molecular docking-based prediction of the molecular targets and signaling pathways of ginseng in the treatment of Parkinsonʼs disease. Nat Prod Commun 2022; 17: 1-9
58 Wu YH, Liu H, Wang YL, Sheng HD, Chen ZL, Xun DJ, Wu HM, Xiao S, Bi Y, Wang Y. DiHuangYin decoction protects dopaminergic neurons in a Parkinsonʼs disease model by alleviating peripheral inflammation. Phytomedicine 2022; 105: 154357
59 Lin DT, Zeng YD, Tang DY, Cai YM. Study on the mechanism of Liuwei Dihuang pills in treating Parkinsonʼs disease based on network pharmacology. Biomed Res Int 2021; 2021: 4490081
60 Dhingra H, Gaidhane SA. Huntingtonʼs disease: Understanding its novel drugs and treatments. Cureus 2023; 15: e47526
61 Garcia-Gonzalez X, Cubo E, Simon-Vicente L, Mariscal N, Alcaraz R, Aguado L, Rivadeneyra-Posadas J, Sanz-Solas A, Saiz-Rodriguez M. Pharmacogenetics in the treatment of Huntingtonʼs disease: Review and future perspectives. J Pers Med 2023; 13: 385
62 Csehi R, Molnar V, Fedor M, Zsumbera V, Palasti A, Acsai K, Grosz Z, Nemeth G, Molnar MJ. The improvement of motor symptoms in Huntingtonʼs disease during cariprazine treatment. Orphanet J Rare Dis 2023; 18: 375
63 Kalathur RKR, Pedro Pinto J, Sahoo B, Chaurasia G, Futschik ME. HDNetDB: A molecular interaction database for network-oriented investigations into Huntingtonʼs disease. Sci Rep 2017; 7: 5216
64 Zhang D, Zhang Y, Gao Y, Chai X, Pi R, Chan G, Hu Y. Translating traditional herbal formulas into modern drugs: A network-based analysis of Xiaoyao decoction. Chin Med 2020; 15: 25
65 Patil N, Dhariwal R, Mohammed A, Wei LS, Jain M. Network pharmacology-based approach to elucidate the pharmacologic mechanisms of natural compounds from Dictyostelium discoideum for Alzheimerʼs disease treatment. Heliyon 2024; 10: e28852
66 Qiu M, Zhang J, Wei W, Zhang Y, Li M, Bai Y, Wang H, Meng Q, Guo DA. Integrated UPLC/Q-TOF-MS/MS analysis and network pharmacology to reveal the neuroprotective mechanisms and potential pharmacological ingredients of Aurantii Fructus Immaturus and Aurantii Fructus . Pharmaceuticals (Basel) 2024; 17: 239
67 Virdee JK, Saro G, Fouillet A, Findlay J, Ferreira F, Eversden S, OʼNeill MJ, Wolak J, Ursu D. A high-throughput model for investigating neuronal function and synaptic transmission in cultured neuronal networks. Sci Rep 2017; 7: 14498
68 Gao J, Sterling E, Hankin R, Sikal A, Yao Y. Therapeutics targeting skeletal muscle in amyotrophic lateral sclerosis. Biomolecules 2024; 14: 878
69 Lu L, Deng Y, Xu R. Current potential therapeutics of amyotrophic lateral sclerosis. Front Neurol 2024; 15: 1402962
70 Genge A, Wainwright S, Vande Velde C. Amyotrophic lateral sclerosis: Exploring pathophysiology in the context of treatment. Amyotroph Lateral Scler Frontotemporal Degener 2024; 25: 225-236
71 Neupane P, Thada PK, Singh P, Faisal AR, Rai N, Poudel P, Waleed MS, Quinonez J, Ruxmohan S, Jain E. Investigating edaravone use for management of Amyotrophic Lateral Sclerosis (ALS): A narrative review. Cureus 2023; 15: e33746
72 Li R, Han X, Wang Q, Wang C, Jing W, Zhang H, Wang J, Pan W. Network pharmacology analysis and clinical efficacy of the traditional Chinese medicine Bu-Shen-Jian-Pi. Part 3: Alleviation of hypoxia, muscle-wasting, and modulation of redox functions in amyotrophic lateral sclerosis. Int J Clin Pharmacol Ther 2024; 62: 169-177
73 Lin J, Wang J, Wang C, Shan Y, Jing W, Fei Z, Pan W. Network pharmacology analysis and clinical efficacy of the traditional Chinese medicine Bu-Shen-Jian-Pi. Part 1: Biogenic components and identification of targets and signaling pathways in amyotrophic lateral sclerosis patients. Int J Clin Pharmacol Ther 2024; 62: 155-161
74 Tang X, Zhan Y, Yang B, Du B, Huang J. Exploring the mechanism of Semen Strychni in treating amyotrophic lateral sclerosis based on network pharmacology. Medicine (Baltimore) 2023; 102: e35101
75 Li X, Tian Y, Wu H, Wang T. Network pharmacology and molecular docking to unveil the mechanism of Shudihuang against Amyotrophic Lateral Sclerosis. Curr Pharm Des 2023; 29: 1535-1545
76 Liu X, Xiao X, Han X, Yao L, Lan W. A new therapeutic trend: Natural medicine for ameliorating ischemic stroke via PI3K/Akt signaling pathway. Molecules 2022; 27: 7963
77 Noor F, Tahir Ul Qamar M, Ashfaq UA, Albutti A, Alwashmi ASS, Aljasir MA. Network pharmacology approach for medicinal plants: Review and assessment. Pharmaceuticals (Basel) 2022; 15: 572
78 Carrillo-Mora P, Landa-Solis C, Valle-Garcia D, Luna-Angulo A, Aviles-Arnaut H, Robles-Banuelos B, Sanchez-Chapul L, Rangel-Lopez E. Kynurenines and inflammation: A remarkable axis for multiple sclerosis treatment. Pharmaceuticals (Basel) 2024; 17: 983
79 Lipphardt M, Wallbach M, Koziolek MJ. Plasma exchange or immunoadsorption in demyelinating diseases: A meta-analysis. J Clin Med 2020; 9: 1597
80 Mukhatayev Z, Dellacecca ER, Cosgrove C, Shivde R, Jaishankar D, Pontarolo-Maag K, Eby JM, Henning SW, Ostapchuk YO, Cedercreutz K, Issanov A, Mehrotra S, Overbeck A, Junghans RP, Leventhal JR, Le Poole IC. Antigen specificity enhances disease control by tregs in vitiligo. Front Immunol 2020; 11: 581433
81 Armer JM, Ballman KV, McCall L, Armer NC, Sun Y, Udmuangpia T, Hunt KK, Mittendorf EA, Byrd DR, Julian TB, Boughey JC. Lymphedema symptoms and limb measurement changes in breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection: results of American College of Surgeons Oncology Group (ACOSOG) Z1071 (Alliance) substudy. Support Care Cancer 2019; 27: 495-503
82 Noor F, Rehman A, Ashfaq UA, Saleem MH, Okla MK, Al-Hashimi A, AbdElgawad H, Aslam S. Integrating network pharmacology and molecular docking approaches to decipher the multi-target pharmacological mechanism of Abrus precatorius L. acting on diabetes. Pharmaceuticals (Basel) 2022; 15: 414